APA

Anderson K. M., Califf R. M., Stone G. W., Neumann F. J., Montalescot G., Miller D. P., Ferguson J. J., Willerson J. T., Weisman H. F. & Topol E. J. (20010712). Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary intervention. : Journal of the American College of Cardiology.

Chicago

Anderson K M, Califf R M, Stone G W, Neumann F J, Montalescot G, Miller D P, Ferguson J J, Willerson J T, Weisman H F and Topol E J. 20010712. Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary intervention. : Journal of the American College of Cardiology.

Harvard

Anderson K. M., Califf R. M., Stone G. W., Neumann F. J., Montalescot G., Miller D. P., Ferguson J. J., Willerson J. T., Weisman H. F. and Topol E. J. (20010712). Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary intervention. : Journal of the American College of Cardiology.

MLA

Anderson K M, Califf R M, Stone G W, Neumann F J, Montalescot G, Miller D P, Ferguson J J, Willerson J T, Weisman H F and Topol E J. Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary intervention. : Journal of the American College of Cardiology. 20010712.